Compare
Longevity companies, side by side.
Every company profiled on variis, on the same table. Exchange, category, market cap, status, all sourced and dated.
4 of 4 companies. Scroll horizontally on narrow screens.
| Attribute | Eli LillyNYSE | Insilico MedicineHKEX | MesoblastASX | Unity BiotechnologyNASDAQ |
|---|---|---|---|---|
| Exchange | NYSE | HKEX | ASX | NASDAQ |
| Ticker | NYSE:LLY | HKEX:3696 | ASX:MSB / NASDAQ:MESO | NASDAQ:UBX |
| Secondary listing | – | – | – | – |
| Market cap | ~US$1.15T | ~HK$23–24B (US$3.0B) | ~A$2.6–2.8B | ~US$13–20M (collapsed) |
| Category | GLP-1 and metabolic | AI drug discovery | ASX listed | Geroscience |
| Headquarters | Indianapolis | Hong Kong / Boston | Melbourne | South San Francisco |
| Status | Active | Active | Active | Active |
| Longevity exposure | Tirzepatide + oral orforglipron; XPRIZE Healthspan sponsor. | Generative-AI drug discovery (Pharma.AI). | First FDA-approved MSC product (Ryoncil). | Senolytics, clearing senescent cells. |
| Recent inflection | Oral orforglipron ("Foundayo") FDA-approved 1 Apr 2026. | IPO 30 Dec 2025, largest 2025 HK biotech IPO; Temasek cornerstone. | Apr 2026 FDA IND clearance for Ryoncil in Duchenne MD. | Lead UBX1325 Ph2b FAILED Apr 2026; senolytic thesis impaired. |
Not investment advice.